公开(公告)号：US20190117770A1

公开(公告)日：2019-04-25

申请号：US16139379

申请日：2018-09-24

申请人： Biotest AG ,  ImmunoGen, Inc.

发明人： Gregor Schulz ,  Frank Osterroth ,  Thomas Haeder ,  Christoph Bruecher ,  Gabriele Niemann ,  Andre Engling ,  Christoph Uherek ,  Benjamin Daelken ,  Andrea Wartenberg-Demand ,  Chantal Zuber ,  Marcus Gutscher ,  Katrin Bernoester ,  Martin Koenig

IPC分类号： A61K39/395 ,  A61K47/68

摘要： Disclosed is a method and composition for treating a disease associated with target cells expressing CD138 in a multiple dose regimen. An immunoconjugate comprising an engineered targeting antibody targeting CD138 expressing cells and an effector molecule is administered in a multiple dose regimen. The multiple dose regimen comprises at least two doses and the aggregate dose administered within an active treatment cycle is an aggregate maximum tolerable dose (AMTD) or a fraction of the AMTD. The AMTD and/or said fraction exceeds the dose resulting in dose limiting toxicity (DLT) and/or exceeds the maximum tolerable dose (MTD) when the immunoconjugate is administered as a single dose, including as part of a multiple single dose regimen within said active treatment cycle.

公开(公告)号：US20140010828A1

公开(公告)日：2014-01-09

申请号：US13708014

申请日：2012-12-07

申请人： ImmunoGen, Inc. ,  Biotest AG

发明人： Gregor Schulz ,  Frank Osterroth ,  Thomas Haeder ,  Christoph Bruecher ,  Gabriele Niemann ,  Andre Engling ,  Christoph Uherek ,  Benjamin Daelken ,  Andrea Wartenberg-Demand ,  Chantal Zuber ,  Marcus Gutscher ,  Katrin Bernoester ,  Martin Koenig

IPC分类号： A61K39/395

CPC分类号： A61K39/39558 ,  A61K47/6809 ,  A61K47/6851

摘要： Disclosed is a method and composition for treating a disease associated with target cells expressing CD138 in a multiple dose regimen. An immunoconjugate comprising an engineered targeting antibody targeting CD138 expressing cells and an effector molecule is administered in a multiple dose regimen. The multiple dose regimen comprises at least two doses and the aggregate dose administered within an active treatment cycle is an aggregate maximum tolerable dose (AMTD) or a fraction of the AMTD. The AMTD and/or said fraction exceeds the dose resulting in dose limiting toxicity (DLT) and/or exceeds the maximum tolerable dose (MTD) when the immunoconjugate is administered as a single dose, including as part of a multiple single dose regimen within said active treatment cycle.

摘要翻译： 公开了一种用于治疗与多剂量方案中表达CD138的靶细胞相关的疾病的方法和组合物。 包含靶向CD138表达细胞和效应分子的工程化靶向抗体的免疫缀合物以多剂量方案给药。 多剂量方案包括至少两个剂量，并且在活性治疗周期内施用的总剂量是聚集体最大可耐受剂量（AMTD）或AMTD的一部分。 当免疫缀合物以单一剂量施用时，AMTD和/或所述级分超过导致剂量限制性毒性（DLT）的剂量和/或超过最大可耐受剂量（MTD），包括作为所述多发单剂量方案的一部分 积极的治疗周期。

公开(公告)号：US20160185854A1

公开(公告)日：2016-06-30

申请号：US14812469

申请日：2015-07-29

申请人： BIOTEST AG

发明人： Elmar Kraus ,  Christoph Bruecher ,  Benjamin Daelken ,  Matthias Germer ,  Steffen Zeng ,  Frank Osterroth ,  Silke Aigner ,  Gregor Schulz ,  Christoph Uherek

IPC分类号： C07K16/28 ,  C07K16/30

CPC分类号： C07K16/28 ,  A61K47/6803 ,  A61K47/6849 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2896 ,  C07K16/30 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92

摘要： Disclosed is a human murine chimeric antibody which substantially retains the antigen binding region of its murine counterpart and displays improved binding affinities to the antigen and/or more homogenous binding to target cells.

公开(公告)号：US10117932B2

公开(公告)日：2018-11-06

申请号：US13708014

申请日：2012-12-07

申请人： Biotest AG ,  ImmunoGen, Inc.

发明人： Gregor Schulz ,  Frank Osterroth ,  Thomas Haeder ,  Christoph Bruecher ,  Gabriele Niemann ,  Andre Engling ,  Christoph Uherek ,  Benjamin Daelken ,  Andrea Wartenberg-Demand ,  Chantal Zuber ,  Marcus Gutscher ,  Katrin Bernoester ,  Martin Koenig

IPC分类号： A61K49/00 ,  A61K39/00 ,  A61K39/395 ,  A61K47/68

摘要： Disclosed is a method and composition for treating a disease associated with target cells expressing CD138 in a multiple dose regimen. An immunoconjugate comprising an engineered targeting antibody targeting CD138 expressing cells and an effector molecule is administered in a multiple dose regimen. The multiple dose regimen comprises at least two doses and the aggregate dose administered within an active treatment cycle is an aggregate maximum tolerable dose (AMTD) or a fraction of the AMTD. The AMTD and/or said fraction exceeds the dose resulting in dose limiting toxicity (DLT) and/or exceeds the maximum tolerable dose (MTD) when the immunoconjugate is administered as a single dose, including as part of a multiple single dose regimen within said active treatment cycle.